- BBB announcement on job scams
- FBI Cyber Crime resource page
Full-Time
Confirmed live in the last 24 hours
Biotechnology firm specializing in genetic testing
$80k - $100k/yr
Junior, Mid
Company Historically Provides H1B Sponsorship
Memphis, TN, USA
25-50% travel required
Get referrals →
You have ways to get a Natera referral from your network.
Applications through a referral are 3x more likely to get an interview!
Upload your resume to see how it matches 4 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
Natera focuses on genetic testing and diagnostics, providing advanced solutions for cancer patients, transplant patients, and individuals assessing hereditary health risks. Their core technology involves cell-free DNA (cfDNA) testing, which helps detect minimal traces of cancer and assess the health of transplanted organs. Natera differentiates itself by offering specialized tests like the Signatera ctDNA test and Panorama NIPT for prenatal screening, along with remote genetic counseling services. The company's goal is to enhance patient care through accurate testing and personalized guidance.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Austin, Texas
Founded
2004
Help us improve and share your feedback! Did you find this helpful?
Flexible medical plans
Investment options
Time off
Workplace perks
Natera announces broad clinical launch of ultra-sensitive signatera(tm) genome MRD test.
DnB Asset Management AS invests $235,000 in Natera, Inc. (NASDAQ:NTRA).
AUSTIN, Texas - (BUSINESS WIRE) - Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, announced that it will share results from the DEFINE-HT study in a late-breaking oral presentation at the International Society for Heart and Lung Transplantation (ISHLT) 45th Annual Meeting on April 29, 2025.
Last week, Natera (NasdaqGS:NTRA) announced a strategic expansion of its Board of Directors with the appointment of Monica Bertagnolli.
Natera launches HEROES trial for breast cancer treatment.